WS Investor
25 Mar 2026, 21:16
Thermo Fisher completes $8.9 billion acquisition of Clario
March 24, 2026 — Thermo Fisher Scientific has completed its $8.875 billion acquisition of Clario Holdings, strengthening its position in clinical research and data-driven drug development.
Clario, a provider of endpoint data solutions for clinical trials, will be integrated into Thermo Fisher’s Laboratory Products and Biopharma Services segment. The company’s platform supports digital data collection and analysis across all phases of clinical trials and has contributed to around 70% of recent FDA and EMA novel drug approvals.
Thermo Fisher expects the acquisition to deliver strong financial returns, including double-digit internal rates of return and approximately $175 million in synergies by year five. The deal is also projected to contribute $0.45 to adjusted earnings per share in the first year.
The company said the acquisition enhances its ability to accelerate innovation and improve decision-making for pharmaceutical and biotech customers.
Business Wire
March 24, 2026 — Thermo Fisher Scientific has completed its $8.875 billion acquisition of Clario Holdings, strengthening its position in clinical research and data-driven drug development.
Clario, a provider of endpoint data solutions for clinical trials, will be integrated into Thermo Fisher’s Laboratory Products and Biopharma Services segment. The company’s platform supports digital data collection and analysis across all phases of clinical trials and has contributed to around 70% of recent FDA and EMA novel drug approvals.
Thermo Fisher expects the acquisition to deliver strong financial returns, including double-digit internal rates of return and approximately $175 million in synergies by year five. The deal is also projected to contribute $0.45 to adjusted earnings per share in the first year.
The company said the acquisition enhances its ability to accelerate innovation and improve decision-making for pharmaceutical and biotech customers.
Business Wire
